Poland· PL-100495199
Exblifep
A cefepim und beta-lactamase-inhibitor product containing cefepimi dihydrochloridum monohydratum + enmetazobactamum, registered in Poland by Advanz Pharma Ltd. The same ATC class is registered in 9 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Cefepim und beta-lactamase-inhibitor is registered in 9 of 19 countries.
Countries holding a registration under ATC J01DE51 (cefepim und beta-lactamase-inhibitor), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 6 of them publish a price we can compare per daily dose
Cefepim und beta-lactamase-inhibitor · ATC J01DE51
9 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
The record
At a glance
URPL (Poland)- Active substance
- Cefepimi dihydrochloridum monohydratum + Enmetazobactamum
- Manufacturer
- Advanz Pharma Ltd
- Country
- Poland (PL)
- ATC code
- J01DE51
- ATC class
- Cefepim und Beta-Lactamase-Inhibitor
- Defined daily dose
- 6 g, P
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Cefepim und beta-lactamase-inhibitor in 10 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaEXBLIFEPADVANZ PHARMA Limited, Dublin
- SpainEXBLIFEP 2 G/0,5 G POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSIONAdvanz Pharma Limited
- FinlandEXBLIFEPAdvanz Pharma Limited
- FranceEXBLIFEP 2 g/0,5 g, poudre pour solution à diluer pour perfusionADVANZ PHARMA LIMITED
- United KingdomExblifep 2g/0.5g powder for concentrate for solution for infusion vialsAdvanz Pharma
- IrelandEXBLIFEP 2 g/0.5 g powder for concentrate for solution for infusionAdvanz Pharma Limited
- IcelandEXBLIFEPADVANZ PHARMA Limited
- NetherlandsEXBLIFEP 2 g/0,5 g, poeder voor concentraat voor oplossing voor infusieAdvanz Pharma Limited
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Exblifep
- Liechtenstein · Exblifep
- Norway · Exblifep
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ddb21606-1e84-430e-9b6f-f4e2ee2d8e87 GET /v1/drugs/ddb21606-1e84-430e-9b6f-f4e2ee2d8e87?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Proszek do sporządzania koncentratu roztworu do infuzji",
"source": "urpl",
"strength": "2 g + 0,5 g",
"packaging": "Rp ¦ EU/1/24/1794/001 ¦ 153943\n10 fiol. 20 ml",
"substance": "Cefepimi dihydrochloridum monohydratum 2 g + Enmetazobactamum 0.5 g",
"common_name": "Cefepimi dihydrochloridum monohydratum + Enmetazobactamum",
"pl_product_id": "100495199",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about cefepim und beta-lactamase-inhibitor.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.